Loading
A phase 3 trial of Trastuzumab brengitecan, Pertuzumab, Trastuzumab in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07518173 by Sichuan Baili Pharmaceutical Co., Ltd., with 596 participants planned, started 2026-04-21 and due to reach its primary completion in 2029-12. Interventions recorded: BL-M07D1, Pertuzumab, Trastuzumab, Docetaxel. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Docetaxel.
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Trastuzumab.
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares SystImmune / Sichuan Biokin, Docetaxel, Cytotoxic chemotherapy.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/